An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Opsumit

Chemical Namemacitentan
Dosage FormTablet (oral; 10mg)
Drug ClassReceptor antagonists
SystemCardiovascular
CompanyActelion Pharmaceuticals US, Inc.
Approval Year2013

Indication

  • For the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization.
Last updated on 4/29/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Opsumit (macitentan) Prescribing Information2013Actelion Pharmaceuticals US, Inc., South San Francisco, CA
Document TitleYearSource
A Bayesian network meta-analysis of add-on drug therapies specific for pulmonary arterial hypertension.2019Annals of Pharmacotherapy
Efficacy and safety of the use of pulmonary arterial hypertension pharmacotherapy in patients with pulmonary hypertension secondary to left heart disease: A systematic review. 2019Pharmacotherapy
Systematic review of randomized controlled trials of endothelin receptor antagonists for pulmonary arterial hypertension. 2016Lung
Clinical adverse effects of endothelin receptor antagonists: Insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials.2016Journal of the American Heart Association
Document TitleYearSource
2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.2016European Heart Journal